36 results on '"Claudia Fabrizio"'
Search Results
2. HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ?
- Author
-
Giuseppe Bruno, Annalisa Saracino, Luigia Scudeller, Claudia Fabrizio, Raffaele Dell’Acqua, Eugenio Milano, Michele Milella, Nicoletta Ladisa, Laura Monno, and Gioacchino Angarano
- Subjects
Direct-acting antivirals ,DAAs ,SVR ,Safety ,HIV/HCV co-infection ,Real world ,Infectious and parasitic diseases ,RC109-216 - Abstract
Background: Direct-acting antiviral (DAA)-based treatment of hepatitis C virus (HCV) has been associated with high sustained virological response (SVR) rates and good tolerability in randomized clinical trials. This study was performed to assess the safety and effectiveness of DAAs in both HCV mono-infected and HIV/HCV co-infected patients. Methods: All consecutive HCV-infected patients, including HIV/HCV co-infected patients, receiving DAA-based treatment from February 2015 to September 2016 at the study clinic were included. Clinical, virological, and biochemical data were retrieved. The primary end-point was the SVR12 (HCV RNA undetectable 12 weeks after the end of treatment) is commonly used worldwide. The secondary end-point was the safety profile of DAAs during the treatment period. Results: A total of 382 patients were included; 62 were HIV/HCV co-infected. Cirrhosis was found in 256 patients (67.4%). SVR12 was achieved in 365/382 (95.5%) individuals (58/62 HIV/HCV co-infected, 93.5%) in the intention-to-treat (ITT) analysis. A platelet count 20 kPa (OR 3.05, 95% CI 1.03–8.96, p = 0.04), and Model for End-Stage Liver Disease (MELD) score >10 (OR 5.27, 95% CI 1.16–23.8, p = 0.03) were associated with lower SVR rates. On multivariate analysis, only genotype 3 infection remained a negative predictor of SVR (OR 21.6, 95% CI 3.81–123, p = 0.001). Treatment discontinuation was observed in 10 subjects. Severe adverse events (SAEs) occurred in 17 patients (4.5%). Conclusions: High SVR12 rates were observed in both HCV mono-infected and HIV/HCV co-infected individuals. Overall, DAA-based treatment was safe and there were no differences in terms of SAEs and treatment discontinuation between the two groups.
- Published
- 2017
- Full Text
- View/download PDF
3. An intricate case of multidrug resistant Plasmodium falciparum isolate imported from Cambodia
- Author
-
Raffaele Dell’Acqua, Claudia Fabrizio, Francesco Di Gennaro, Sergio Lo Caputo, Annalisa Saracino, Michela Menegon, Mariangela L’Episcopia, Carlo Severini, Laura Monno, Francesco Castelli, and Gioacchino Angarano
- Subjects
Malaria, Vivax ,Malaria, Falciparum ,Malaria ,Drug resistance ,Multiple ,Antimalarials ,Arctic medicine. Tropical medicine ,RC955-962 ,Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Background Imported cases of multidrug resistant Plasmodium falciparum and treatment failure with artemisinin-based regimens, although rare, have been described also in Western countries and their management is often challenging. This is also due to an inadequate knowledge and implementation of health prevention measures. Case report A complex case of imported malaria caused by Plasmodium vivax/P. falciparum isolates in a patient who was not taking chemoprophylaxis while he was travelling in Cambodia is reported in this article. After failures of artemisinin-based and both oral and intravenous quinine-based regimens, a multidrug resistant P. falciparum was detected. The patient was successfully treated with atovaquone–proguanil. Conclusions This experience highlights the importance of a careful management that should be based not only on the most up-to-date guidelines, but also on the awareness of a rapidly evolving scenario.
- Published
- 2017
- Full Text
- View/download PDF
4. HIV-1 coreceptor tropism: A syllogistic connection with The Veterans Aging Cohort Study Index and the CD4/CD8 ratio.
- Author
-
Armando Leone, Nicolò de Gennaro, Claudia Fabrizio, Luigia Scudeller, Luciana Lepore, Antonella Lagioia, Grazia Punzi, Annalisa Saracino, Gioacchino Angarano, and Laura Monno
- Subjects
Medicine ,Science - Abstract
BACKGROUND:The association between X4 virus and an increased risk of non-AIDS-events has been reported. Morbidity/mortality due to non-AIDS events, which are properly predicted by the CD4/CD8 ratio and VACS index, have become particularly remarkable in HIV-infected patients receiving effective combined antiretroviral therapy (cART). METHODS:We verified the validity of the syllogism: as HIV-tropism (CRT) contributes to the onset of non-AIDS events which are successfully predicted by the CD4/CD8 ratio and VACS index, then CRT correlates with these two variables. The CD4/CD8 ratio and VACS index at baseline and overtime were analyzed according to CRT tested before the first successful cART regimen in newly-diagnosed patients. RESULTS:Patients with R5 variants had a significantly lower baseline VACS percentage risk [mean (95%CI):18.2%(16.1-20.3) vs 24.3%(18.2-22.5), p = 0.002] and higher baseline CD4/CD8 ratio [mean (95%CI):0.43 (0.38-0.47) vs 0.28 (0.19-0.36), p = 0.002] than non-R5 patients. After an initial drop, VACS increased again in R5 and non-R5 patients and the two trend curves almost overlapped. The CD4/CD8 ratio had an increasing trend in both R5 and non-R5 patients; however, even though non-R5 patients had a greater gain of CD4+, they maintained a lower CD4/CD8 ratio at any time point. CONCLUSION:Our study confirms an association between pre-therapy CRT, CD4/CD8 ratio and VACS. A successful cART regimen positively affects the CD4/CD8 ratio; however, the disadvantage conferred by a non-R5 CRT is maintained overtime. The restoration of VACS in all patients could be directly due to variables included in the VACS calculation and to factors that adversely influence these variables.
- Published
- 2019
- Full Text
- View/download PDF
5. Cidofovir for treating complicated monkeypox in a man with acquired immune deficiency syndrome
- Author
-
Claudia Fabrizio, Giuseppe Bruno, Letizia Cristiano, and Giovanni Battista Buccoliero
- Subjects
Microbiology (medical) ,Infectious Diseases ,General Medicine - Abstract
In July 23, the World Health Organization (WHO) declared monkeypox (MPX) a global health emergency of international concern given its rapid spread. So far, most current MPX outbreaks have involved young men who have sex with men (MSM), although with overall mild, self-limiting clinical manifestations. We aim to describe the case of an HIV positive young MSM whose status of immune compromission probably contributed to a more severe clinical course of MPX disease, thus requiring hospitalization and antiviral treatment. He was effectively treated with Cidofovir that may be considered as a valuable component of a multi-faceted management of severe MPX.
- Published
- 2022
6. Cidofovir for treating complicated monkeypox in a man with severe acquired immunodeficiency
- Author
-
Claudia Fabrizio, Giuseppe Bruno, Letizia Cristiano, and Giovanni Battista Buccoliero
- Abstract
On July 23, the World Health Organization (WHO) declared monkeypox (MPX) a global health emergency of international concern given its rapid spreading. So far, most current MPX outbreaks have involved young men who have sex with men (MSM), although with overall mild, self-limiting clinical manifestations. We aim to describe the case of a young MSM, HIV positive, whose status of utter immune suppression probably contributed to worsen the clinical course of MPX disease, thus requiring hospitalization and antiviral treatment. He was effectively treated with Cidofovir that may be a valuable component of a multi-faceted management of severe MPX.
- Published
- 2022
7. Non-nominative arguments, active impersonals, and control in Latin
- Author
-
Michela Cennamo and Claudia Fabrizio
- Abstract
The continuum of control plays a crucial role in the marking of transitivity in Latin, witnessed also by the alternation between the personal and impersonal encoding of eventualities. The present study investigates argument marking with some ‘impersonal’ verbs. These patterns reflect the crystallisation of a seemingly widespread construction in the early stages of the language, probably of Indo-European inheritance, the use of the third-person singular active with an accusative/oblique argument to denote the spontaneous manifestation of an eventuality and the lack of control of the A/S argument, a pattern competing with the passive form for some verbs in this domain. These impersonal constructions in Latin point to the existence of a dependent-marked, agentive-coding subsystem, similar to analogous constructions in languages with semantic alignment. This evidence suggests that Latin is a language with a syntactically based (nominative–accusative) and (dependent-marked) semantically based subsystems of alignment, sensitive to the notion of control.
- Published
- 2022
8. Infinitives and subjecthood between Latin and Old Italian
- Author
-
Claudia Fabrizio
- Abstract
The chapter examines the syntactic behaviour of a special class of non-canonical subjects, namely nominal infinitives, in Latin and in one of its daughter languages, Old Italian. The data show that Latin infinitives can appear in subject function only if the finite verb of the clause belongs to a restricted set of unaccusative predicates, corresponding to states or telic changes of state. In other words, Latin infinitives cannot surface as subjects of unergative and transitive predicates, thus conforming to a widespread cross-linguistic trend concerning non-canonical subjects. Vice versa, the distribution of subject infinitives in Old Italian is unrestricted, insofar as they are eligible to subjecthood regardless of the finite verb of the clause. The hypothesis this chapter explores is that the change which took place from Latin to Old Italian, involving the syntactic status of nominal infinitives, might have started from the clauses with a finite experiencer predicate.
- Published
- 2022
9. Monkeypox in a 71-year-old woman
- Author
-
Giuseppe Bruno, Claudia Fabrizio, Leonardo Rodano, and Giovanni Battista Buccoliero
- Subjects
Infectious Diseases ,Virology - Published
- 2022
10. Tocilizumab and corticosteroids for COVID-19 treatment in elderly patients
- Author
-
Davide Fiore Bavaro, Giuseppe Bruno, Claudia Fabrizio, Sergio Carbonara, Irene Francesca Bottalico, Gaetano Brindicci, Antonio Mastroianni, Giovanni Buccoliero, Sonia Greco, Sergio Lo Caputo, Teresa Santantonio, Gioacchino Angarano, Annalisa Saracino, Laura Monno, Carmen Rita Santoro, Flavia Balena, and Angela Calamo
- Subjects
Aging ,medicine.medical_specialty ,medicine.drug_class ,business.industry ,Secondary infection ,Mortality rate ,medicine.disease ,Logistic regression ,Pneumonia ,chemistry.chemical_compound ,Tocilizumab ,medicine.anatomical_structure ,chemistry ,Internal medicine ,Throat ,medicine ,Corticosteroid ,Geriatrics and Gerontology ,Adverse effect ,business - Abstract
Background. The mortality rate for coronavirus disease-19 (COVID-19) increases with age. Some anti-inflammatory drugs such as tocilizumab or steroids have been proposed for the treatment of severe disease; however, few data are available in the elderly. Methods. A retrospective case-series of patients hospitalized between March 1st and June 15th, 2020 with confirmed COVID-19 by RT-PCR testing on throat/nasopharyngeal swabs and age ≥ 65 years was analysed. Patients were retrospectively divided into three groups according to the chosen treatment [standard of care (SOC), tocilizumab or corticosteroids] and patient characteristics and occurrence of adverse events were compared among groups. Results. Overall, 206 patients were included, 148 treated with standard of care, 42 with steroids and 16 with tocilizumab. Patients treated with steroids or Tocilizumab presented more frequently with fever (p = .003), dyspnea (p < .001), bilateral opacities/infiltrates at chest X-ray (p =.026) or CT-scan (p = .020), and more frequently required non-invasive/invasive ventilation (p < .001). Crude mortality was 27%, without differences among groups (p = .074). No specific adverse events were observed during/after the administration of steroids or tocilizumab; however, a trend towards an increased risk of secondary infections was described compared to SOC (p = .097). At multivariate logistic regression, only tocilizumab administration was an independent predictor of secondary infections (aOR = 6.72, 95% CI = 1.43-31.39, p = .015). Conclusions. Tocilizumab and corticosteroid could have a possible role for severe form of pneumonia in course of COVID-19 also in elderly patients, even if great attention to the monitoring of infectious complications should be paid in this special population.
- Published
- 2020
11. Pharmacogenomics and Pharmacogenetics: In Silico Prediction of Drug Effects in Treatments for Novel Coronavirus SARS-CoV2 Disease
- Author
-
Salvatore Pisconti, Pier Luigi Surico, Claudia Fabrizio, Andrea Cacciamani, Raffaele Palmirotta, Agnese Re, Francesca Romano, Raffaele Di Francia, Gerardo D'Amato, Alessandra Micera, Concetta Cafiero, and Delio Monaco
- Subjects
0301 basic medicine ,Pharmacology ,PharmGKB ,business.industry ,In silico ,Context (language use) ,Genome browser ,Computational biology ,Precision medicine ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Pharmacogenomics ,Molecular Medicine ,Ensembl ,Medicine ,business ,Pharmacogenetics - Abstract
The latest developments in precision medicine allow the modulation of therapeutic approaches in different pathologies on the basis of the specific molecular characterization of the patient. This review of the literature coupled with in silico analysis was to provide a selected screening of interactions between single-nucleotide polymorphisms (SNPs) and drugs (repurposed, investigational, and biological agents) showing efficacy and toxicityin counteracting Covid-19 infection. In silico analysis of genetic variants related to each drug was performed on such databases as PharmGKB, Ensembl Genome Browser, www.drugs.com, and SNPedia, with an extensive literature review of papers (to May 10, 2020) on Covid-19 treatments using Medline, Embase, International Pharmaceutical Abstracts, PharmGKB, and Google Scholar. The clinical relevance of SNPs, known as both drug targets and markers, considering genetic variations with known drug responses, and the therapeutic consequences are discussed. In the context of clinical treatment of Covid-19, including infection prevention, control measures, and supportive care, this review highlights the importance of a personalized approach in the final selection of therapy, which is probably essential in the management of the Covid-19 pandemic.
- Published
- 2020
12. Variability OF HIV-1 V2 env domain for integrin binding: Clinical correlates
- Author
-
Claudia Fabrizio, Flavia Balena, Antonella Lagioia, Luciana Lepore, Davide Fiore Bavaro, Annalisa Saracino, Gioacchino Angarano, Laura Monno, and Luigia Scudeller
- Subjects
Integrins ,Glycosylation ,Amino Acid Motifs ,Integrin ,Human immunodeficiency virus (HIV) ,HIV Infections ,Tripeptide ,HIV Envelope Protein gp120 ,Biology ,medicine.disease_cause ,α4β7 integrin ,03 medical and health sciences ,chemistry.chemical_compound ,Virology ,medicine ,Humans ,Clinical significance ,030304 developmental biology ,Integrin binding ,0303 health sciences ,Binding Sites ,Polymorphism, Genetic ,Host Microbial Interactions ,030302 biochemistry & molecular biology ,Sequence Analysis, DNA ,chemistry ,HIV-1 ,biology.protein ,Protein Binding ,Homing (hematopoietic) - Abstract
The HIV V2179-181 (HXB2 numbering) tripeptide mediates binding to α4β7 integrin, which is responsible for GALT homing. Our study aimed to assess V2 variability in naive HIV-1 infected patients and its association with clinical and viro-immunological features. Gp120 sequences were obtained from 322 subjects; length, potential N-linked glycosylation sites (PNGs), net-charge (NC) and 179-181tripeptide α4β7-binding-motif of V2 were evaluated. At multivariate analysis, lower V2 length and higher NC correlated with low CD4 cells; no association was found with PNGs. A greater variability pertained positions 162-163, 164-167, 169, 175-179, 187, 194 and 195 in B sequences, and 163 and 177 in X4 tropic viruses. LDV was the most common tripeptide. Asp180 was highly conserved; Leu179 was more frequently observed in non-B and in recent infections compared to others, while Val181 was found in recent infections and in MSM. Further studies to deeply explore the clinical significance of these associations are warranted.
- Published
- 2019
13. Peculiar clinical presentation of COVID- 19 and predictors of mortality in the elderly: a Multicentre Retrospective Cohort Study
- Author
-
Giovanni Buccoliero, Annalisa Saracino, Teresa Santantonio, G. Angarano, Carmen Rita Santoro, Giuseppe Bruno, Antonio Mastroianni, Laura Monno, S. Lo Caputo, R. Sulpasso, Sergio Carbonara, Claudia Fabrizio, Irene Francesca Bottalico, Gaetano Brindicci, A. Calamo, Lucia Diella, and Davide Fiore Bavaro
- Subjects
0301 basic medicine ,Microbiology (medical) ,Male ,Dehydration syndrome ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,030106 microbiology ,Infectious and parasitic diseases ,RC109-216 ,Extrapulmonary Manifestations ,Group A ,Group B ,Article ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Elderly ,Internal medicine ,Odds Ratio ,Medicine ,Humans ,Decompensation ,030212 general & internal medicine ,Aged ,Retrospective Studies ,Aged, 80 and over ,Frailty ,business.industry ,SARS-CoV-2 ,COVID-19 ,Retrospective cohort study ,General Medicine ,Odds ratio ,Hospitalization ,Infectious Diseases ,Logistic Models ,Female ,business ,Cohort study - Abstract
Background The spectrum of clinical manifestations of CoronaVirus Disease-19 (COVID-19) is not yet completely known. In elderly, mortality and extra-pulmonary involvement appear to be more frequent than expected. Methods A multicentric-retrospective-case-series of patients hospitalized between March 1st and June 15th, 2020 with confirmed COVID-19 by RT-PCR testing on throat/nasopharyngeal swabs and age ≥65 years was analysed. Based on the “Clinical Frailty Scale” (CFS), patients were classified into three groups according to the resulting score: 1-3 (group A), 4-6 (group B), 7-9 (group C). Results Overall, 206 patients were included. Crude mortality was 27%. According to CFS, on admission, 60 patients (29%) were assigned to group A, 60 (29%) to group B, and 86 (42%) to group C. The following features were significantly more frequent among group C patients in comparison with groups B and A: mental confusion (65% vs 33% vs 7%, respectively, p
- Published
- 2021
14. Short-term outcomes in individuals aged 75 or older with severe coronavirus disease (COVID-19): First observations from an infectious diseases unit in Southern Italy
- Author
-
Giuseppe Bruno, Serena Perelli, Giovanni Buccoliero, and Claudia Fabrizio
- Subjects
Microbiology (medical) ,2019-20 coronavirus outbreak ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Pneumonia, Viral ,Disease ,medicine.disease_cause ,Article ,Betacoronavirus ,Risk Factors ,Pandemic ,Medicine ,Humans ,Pandemics ,Coronavirus ,Aged ,biology ,business.industry ,SARS-CoV-2 ,COVID-19 ,biology.organism_classification ,Virology ,Infectious Diseases ,Italy ,business ,Coronavirus Infections - Abstract
Highlights • In elderly COVID-19 inpatients, admission NEWS2 scores did not predict mortality. • Of components of NEW2 score, only systolic blood pressure predicted mortality. • A high variability in NEW2 score predicted mortality. • NEWS2 score does not consider the degree of supplemental oxygen patients require. • A more sensitive early warning score for COVID-19 is needed.
- Published
- 2020
- Full Text
- View/download PDF
15. Pancreatic injury in the course of coronavirus disease 2019: A not‐so‐rare occurrence
- Author
-
Giuseppe Bruno, Claudia Fabrizio, Carmen Rita Santoro, and Giovanni Buccoliero
- Subjects
2019-20 coronavirus outbreak ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,business.industry ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,medicine.disease ,Virology ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Infectious Diseases ,Internal medicine ,medicine ,Inflammatory cascade ,030211 gastroenterology & hepatology ,030212 general & internal medicine ,Pancreatic injury ,Respiratory system ,business - Abstract
Despite respiratory symptoms are typically found during the course of coronavirus disease 2019 (COVID‐19), gastrointestinal manifestations are increasingly described. However, data regarding COVID‐19‐associated pancreatic injury are still limited, as well as the mechanisms underlying COVID‐19 induced‐pancreatic damage have not been completely clarified. Herein, we described pancreatic abnormalities in six (8.5%) out of 70 patients with COVID‐19 hospitalized in our unit from February 25, 2020 to May 10, 2020. We hypothesized that pancreatic damage may be associated with several factors including direct effect of SARS‐CoV‐2, inflammatory cascade, dehydration and multiple organ dysfunction.This article is protected by copyright. All rights reserved.
- Published
- 2020
- Full Text
- View/download PDF
16. Gp120 substitutions at positions associated with resistance to fostemsavir in treatment-naive HIV-1-positive individuals
- Author
-
Claudia Fabrizio, Gioacchino Angarano, Antonella Lagioia, Annalisa Saracino, Laura Monno, Luciana Lepore, Davide Fiore Bavaro, Anna Volpe, and Eugenio Milano
- Subjects
0301 basic medicine ,Microbiology (medical) ,030106 microbiology ,Population ,Human immunodeficiency virus (HIV) ,HIV Infections ,Biology ,HIV Envelope Protein gp120 ,medicine.disease_cause ,Virus ,Piperazines ,Therapy naive ,03 medical and health sciences ,0302 clinical medicine ,Post-hoc analysis ,medicine ,Humans ,Pharmacology (medical) ,030212 general & internal medicine ,education ,Tropism ,Retrospective Studies ,Pharmacology ,chemistry.chemical_classification ,education.field_of_study ,Virology ,Organophosphates ,Amino acid ,Infectious Diseases ,Fostemsavir ,chemistry ,HIV-1 - Abstract
Objectives Fostemsavir, a novel attachment inhibitor targeting the HIV-1 gp120, has demonstrated wide in vitro activity. However, the high rate of HIV gp120 substitutions could jeopardize its efficacy. We investigated envelope (env) substitutions at positions associated with resistance to fostemsavir in patients with a new HIV-1 diagnosis according to HIV subtype and tropism. Methods Gp120 sequences from 409 subjects were retrospectively analysed and the presence of the L116P, A204D, S375H/M/T, M426L, M434I and M475I mutations was evaluated. Other amino acid changes at the same positions were also recorded. The variability at each amino acid position was evaluated using Shannon entropy. Results The frequency of mutations was: S375T (13.2%); M426L (6.8%); M434I (2.9%); M475I (2.7%); S375H (1.0%)/M (0.8%) and L116P (0.31%). Statistically significant differences were found at positions 375 (R5/non-R5 strains and B/non-B subtypes) and 426 (B/non-B subtypes); post hoc analysis revealed that significance for position 375 was steered by S375T while for position 426 significance was governed by unusual substitutions, in particular M426R (B/non-B, P Conclusions In conclusion, gp120 substitutions were detected in different subtypes and in both R5 and non-R5 variants. Despite the great variability of gp120, the frequency of mutations was low overall and the predominant substitution was S375T, the role of which in reducing fostemsavir efficacy is less substantial.
- Published
- 2019
17. HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ?
- Author
-
Annalisa Saracino, Gioacchino Angarano, Claudia Fabrizio, Michele Milella, Nicoletta Ladisa, Luigia Scudeller, Giuseppe Bruno, Eugenio Milano, Laura Monno, and Raffaele Dell’Acqua
- Subjects
Microbiology (medical) ,Liver Cirrhosis ,Male ,medicine.medical_specialty ,Cirrhosis ,SVR ,Genotype ,Hepatitis C virus ,HIV Infections ,Hepacivirus ,medicine.disease_cause ,Direct-acting antivirals ,Gastroenterology ,Antiviral Agents ,HIV/HCV co-infection ,law.invention ,lcsh:Infectious and parasitic diseases ,03 medical and health sciences ,Liver disease ,0302 clinical medicine ,Randomized controlled trial ,law ,Internal medicine ,Medicine ,Humans ,lcsh:RC109-216 ,030212 general & internal medicine ,Adverse effect ,business.industry ,Coinfection ,virus diseases ,DAAs ,Real world ,General Medicine ,Odds ratio ,Middle Aged ,medicine.disease ,Virology ,Hepatitis C ,Discontinuation ,Infectious Diseases ,Treatment Outcome ,Tolerability ,030211 gastroenterology & hepatology ,Female ,Safety ,business - Abstract
Background Direct-acting antiviral (DAA)-based treatment of hepatitis C virus (HCV) has been associated with high sustained virological response (SVR) rates and good tolerability in randomized clinical trials. This study was performed to assess the safety and effectiveness of DAAs in both HCV mono-infected and HIV/HCV co-infected patients. Methods All consecutive HCV-infected patients, including HIV/HCV co-infected patients, receiving DAA-based treatment from February 2015 to September 2016 at the study clinic were included. Clinical, virological, and biochemical data were retrieved. The primary end-point was the SVR12 (HCV RNA undetectable 12 weeks after the end of treatment) is commonly used worldwide. The secondary end-point was the safety profile of DAAs during the treatment period. Results A total of 382 patients were included; 62 were HIV/HCV co-infected. Cirrhosis was found in 256 patients (67.4%). SVR12 was achieved in 365/382 (95.5%) individuals (58/62 HIV/HCV co-infected, 93.5%) in the intention-to-treat (ITT) analysis. A platelet count 9 /l (odds ratio (OR) 4.12, 95% confidence interval (CI) 1.5–11.3, p =0.006), HCV genotype 3 infection (OR 5.49, 95% CI 1.9–15.7, p =0.002), liver stiffness >20kPa (OR 3.05, 95% CI 1.03–8.96, p =0.04), and Model for End-Stage Liver Disease (MELD) score >10 (OR 5.27, 95% CI 1.16–23.8, p =0.03) were associated with lower SVR rates. On multivariate analysis, only genotype 3 infection remained a negative predictor of SVR (OR 21.6, 95% CI 3.81–123, p =0.001). Treatment discontinuation was observed in 10 subjects. Severe adverse events (SAEs) occurred in 17 patients (4.5%). Conclusions High SVR12 rates were observed in both HCV mono-infected and HIV/HCV co-infected individuals. Overall, DAA-based treatment was safe and there were no differences in terms of SAEs and treatment discontinuation between the two groups.
- Published
- 2017
18. The elderly and direct antiviral agents: Constraint or challenge?
- Author
-
Claudia Fabrizio, Annalisa Saracino, Giuseppe Bruno, Gioacchino Angarano, Eugenio Milano, Sergio Lo Caputo, Michele Milella, Raffaele Dell’Acqua, Luigia Scudeller, and Laura Monno
- Subjects
Male ,Simeprevir ,medicine.medical_specialty ,Pyrrolidines ,Sustained Virologic Response ,Sofosbuvir ,Hepacivirus ,Antiviral Agents ,Group B ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Internal medicine ,Ribavirin ,Humans ,Medicine ,Drug Interactions ,030212 general & internal medicine ,Adverse effect ,Aged ,Retrospective Studies ,Fluorenes ,Hepatology ,business.industry ,Imidazoles ,Gastroenterology ,Valine ,Retrospective cohort study ,Hepatitis C, Chronic ,Surgery ,Logistic Models ,Italy ,chemistry ,Paritaprevir ,Benzimidazoles ,Drug Therapy, Combination ,Female ,030211 gastroenterology & hepatology ,Carbamates ,business ,medicine.drug - Abstract
Background Direct antiviral agents (DAAs) for chronic hepatitis C showed great effectiveness and good safety profile. So far, few data are available about their use in elderly subjects. Aim To assess management, safety and outcome of DAAs treatments in the elderly. Methods This retrospective, single-centre study enrolled all patients aged ≥65 years, compared by age (group A: 65–74 years, group B: ≥75 years), who completed DAAs between February 2015–November 2016. Variables potentially associated to adverse events (AEs) were analyzed. Sustained virological response (SVR) was evaluated at 12-weeks follow-up. Results DAAs were administered to 221 patients aged ≥65 years (males: 112; group A: 130, group B: 91). Prescribed regimens were: sofosbuvir-based: 44 patients (19.9%), simeprevir-based: 25 (15%), ledipasvir-based: 49 (22.2%), daclatasvir-based: 12 (5.4%), paritaprevir/ritonavir + ombitasvir ± dasabuvir: 91 (41.2%). Ribavirin was used in 121 patients. In 58 subjects co-medications were adjusted due to drug interactions. At least one AE occurred in 130 patients, including 13 SAEs, mainly in older subjects (p = 0.04). Female sex (p = 0.04), liver stiffness (p = 0.023), use of simeprevir (p = 0.03) and ribavirin (p = 0.009) were associated with AEs. SVR-12 was achieved in 96,9% of subjects. Conclusions A careful baseline evaluation and a strict monitoring allow to optimise management and outcome of DAAs in elderly.
- Published
- 2017
19. Introduction
- Author
-
Michela Cennamo and Claudia Fabrizio
- Published
- 2019
20. HIV-1 coreceptor tropism: A syllogistic connection with The Veterans Aging Cohort Study Index and the CD4/CD8 ratio
- Author
-
Annalisa Saracino, Antonella Lagioia, Nicolò De Gennaro, Armando Leone, Claudia Fabrizio, Grazia Punzi, Luciana Lepore, Laura Monno, Luigia Scudeller, and Gioacchino Angarano
- Subjects
0301 basic medicine ,Male ,RNA viruses ,Human immunodeficiency virus (HIV) ,CD4-CD8 Ratio ,HIV Infections ,medicine.disease_cause ,Pathology and Laboratory Medicine ,Cohort Studies ,0302 clinical medicine ,Immunodeficiency Viruses ,Risk Factors ,Antiretroviral Therapy, Highly Active ,030212 general & internal medicine ,Veterans ,Multidisciplinary ,HIV diagnosis and management ,Middle Aged ,Italy ,Medical Microbiology ,Viral Pathogens ,Viruses ,Cardiology ,Infectious diseases ,Medicine ,Female ,Pathogens ,Coreceptors ,Cohort study ,Research Article ,Signal Transduction ,Cart ,Adult ,medicine.medical_specialty ,Receptors, CXCR4 ,Receptors, CCR5 ,Science ,Men WHO Have Sex with Men ,Viral diseases ,Microbiology ,03 medical and health sciences ,Internal medicine ,Virology ,Retroviruses ,medicine ,Humans ,Microbial Pathogens ,Medicine and health sciences ,business.industry ,Lentivirus ,Organisms ,Genetic Variation ,Biology and Life Sciences ,HIV ,CD coreceptors ,Cell Biology ,030112 virology ,Antiretroviral therapy ,Diagnostic medicine ,CD4 Lymphocyte Count ,Regimen ,Viral Tropism ,Increased risk ,People and Places ,Coreceptor tropism ,HIV-1 ,Population Groupings ,business ,Sexuality Groupings - Abstract
Background The association between X4 virus and an increased risk of non-AIDS-events has been reported. Morbidity/mortality due to non-AIDS events, which are properly predicted by the CD4/CD8 ratio and VACS index, have become particularly remarkable in HIV-infected patients receiving effective combined antiretroviral therapy (cART). Methods We verified the validity of the syllogism: as HIV-tropism (CRT) contributes to the onset of non-AIDS events which are successfully predicted by the CD4/CD8 ratio and VACS index, then CRT correlates with these two variables. The CD4/CD8 ratio and VACS index at baseline and overtime were analyzed according to CRT tested before the first successful cART regimen in newly-diagnosed patients. Results Patients with R5 variants had a significantly lower baseline VACS percentage risk [mean (95%CI):18.2%(16.1-20.3) vs 24.3%(18.2-22.5), p = 0.002] and higher baseline CD4/CD8 ratio [mean (95%CI):0.43 (0.38-0.47) vs 0.28 (0.19-0.36), p = 0.002] than non-R5 patients. After an initial drop, VACS increased again in R5 and non-R5 patients and the two trend curves almost overlapped. The CD4/CD8 ratio had an increasing trend in both R5 and non-R5 patients; however, even though non-R5 patients had a greater gain of CD4+, they maintained a lower CD4/CD8 ratio at any time point. Conclusion Our study confirms an association between pre-therapy CRT, CD4/CD8 ratio and VACS. A successful cART regimen positively affects the CD4/CD8 ratio; however, the disadvantage conferred by a non-R5 CRT is maintained overtime. The restoration of VACS in all patients could be directly due to variables included in the VACS calculation and to factors that adversely influence these variables.
- Published
- 2019
21. Historical Linguistics 2015 : Selected Papers From the 22nd International Conference on Historical Linguistics, Naples, 27-31 July 2015
- Author
-
Michela Cennamo, Claudia Fabrizio, Michela Cennamo, and Claudia Fabrizio
- Subjects
- Historical linguistics--Congresses
- Abstract
The collection of articles presented in this volume addresses a number of general theoretical, methodological and empirical issues in the field of Historical Linguistics, in different levels of analysis and on different themes: (i) phonology, (ii) morphology, (iii) morphosyntax, (iv) syntax, (v) diachronic typology, (vi) semantics and pragmatics, and (vii) language contact, variation and diffusion. The topics discussed, often in a comparative perspective, feature a variety of languages and language families and cover a wide range of research areas. Novel analyses and often new diachronic data — also from less known and under-investigated languages — are provided to the debate on the principles, mechanisms, paths and models of language change, as well as the relationship between synchronic variation and diachrony. The volume is of interest to scholars of different persuasions working on all aspects of language change.
- Published
- 2019
22. Tuberculosis and diabetes: current state and future perspectives
- Author
-
Giovanni Putoto, Damiano Pizzol, Laura Monno, Claudia Fabrizio, Francesco Di Gennaro, Annalisa Saracino, and Kajal D. Chhaganlal
- Subjects
Gerontology ,medicine.medical_specialty ,Tuberculosis ,business.industry ,030231 tropical medicine ,Public Health, Environmental and Occupational Health ,Developing country ,medicine.disease ,Diabetes Complications ,03 medical and health sciences ,0302 clinical medicine ,Infectious Diseases ,Diabetes mellitus ,Epidemiology ,Diabetes Mellitus ,Global health ,medicine ,Humans ,Parasitology ,030212 general & internal medicine ,business ,Developing Countries - Abstract
This review outlines the association between tuberculosis and diabetes, focusing on epidemiology, physiopathology, clinical aspects, diagnosis and treatment, and evaluates future perspectives, with particular attention to developing countries.
- Published
- 2016
23. COVID-19-associated pulmonary aspergillosis: adding insult to injury
- Author
-
Claudia Fabrizio, Giovanni Buccoliero, and Giuseppe Bruno
- Subjects
Microbiology (medical) ,lcsh:R5-920 ,2019-20 coronavirus outbreak ,Coronavirus disease 2019 (COVID-19) ,business.industry ,media_common.quotation_subject ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,lcsh:QR1-502 ,Microbiology ,Article ,lcsh:Microbiology ,Insult ,Pulmonary aspergillosis ,Infectious Diseases ,Virology ,Immunology ,Medicine ,lcsh:Medicine (General) ,business ,media_common - Published
- 2020
24. Cerebrospinal fluid compartmentalization of HIV-1 and correlation with plasma viral load and blood-brain barrier damage
- Author
-
A. Calamo, G. Angarano, Annalisa Saracino, Luciana Lepore, Davide Fiore Bavaro, Claudia Fabrizio, and Laura Monno
- Subjects
Microbiology (medical) ,Adult ,Male ,Human immunodeficiency virus (HIV) ,HIV Infections ,Blood–brain barrier ,medicine.disease_cause ,Plasma viral load ,Correlation ,Plasma ,Cerebrospinal fluid ,medicine ,Humans ,Retrospective Studies ,business.industry ,General Medicine ,Compartmentalization (psychology) ,Middle Aged ,Viral Load ,Infectious Diseases ,medicine.anatomical_structure ,Blood-Brain Barrier ,Immunology ,HIV-1 ,Csf analysis ,Female ,Plasma Albumin ,business - Abstract
We aimed to evaluate HIV-1 compartmentalization between the cerebrospinal fluid (CSF) and plasma and investigate as to which extent HIV-1 strains in CSF differ from those in blood and whether a correlation with either plasma viral load (pVL) or an altered blood-brain barrier (BBB) does exist.We retrospectively evaluated paired CSF/blood samples collected from 86 HIV+ patients. HIV-RNA quantification, pol (PR/RT), and V3 sequencing were performed. HIV coreceptor tropism (CRT) was inferred (g2p, false-positive rate 10%, FPR). Data of standard CSF analysis were also reviewed; an altered CSF/plasma albumin ratio signified BBB damage. Neurological abnormalities (NA) were recorded.Overall, 32% of patients had a CSF/plasma HIV-RNA ratio 1 (discordance); 3% of patients had detectable CSF HIV-RNA despite suppressed pVL (escape). Discordance was more frequent in ART-treated patients (p 0.001) and in patients with NA (p = 0.016), but was independent of BBB damage (p = 0.65) and AIDS diagnosis (p = 0.96). Finally, CSF/plasma discordance was significantly more frequent (p 0.0001) in patients with lower pVL values ( 10.000 copies/ml). Env divergence 10% was found in 44% of sequences and was associated with ART (p = 0.008) and NA (p = 0.037). Overall, 24% of patients had a discordant CSF/blood CRT. A 100% nucleotide identity was observed in only 7.3% of pol sequences; notably, 10% of patients had resistance-associated mutations in CSF, but not in blood.Our data confirm an independent replication and evolution of HIV within the CSF. A number of factors either hinder or contribute to the compartmentalization of HIV.
- Published
- 2018
25. HIV-RNA decay in paired blood and semen samples of subjects receiving their first dolutegravir-based ART regimen
- Author
-
Nicoletta Ladisa, Annalisa Saracino, Anna Volpe, Gioacchino Angarano, Luigia Scudeller, Katia Falasca, Laura Monno, Antonella Lagioia, Claudia Fabrizio, and Nicolò De Gennaro
- Subjects
0301 basic medicine ,Adult ,Male ,medicine.medical_specialty ,Sexual transmission ,Adolescent ,Anti-HIV Agents ,Pyridones ,Art initiation ,Semen ,HIV Infections ,Piperazines ,03 medical and health sciences ,chemistry.chemical_compound ,Young Adult ,0302 clinical medicine ,Virology ,Internal medicine ,Antiretroviral Therapy, Highly Active ,Oxazines ,medicine ,Humans ,030212 general & internal medicine ,Viral suppression ,HIV Integrase Inhibitors ,Prospective Studies ,business.industry ,Middle Aged ,Viral Load ,Antiretroviral therapy ,Regimen ,030104 developmental biology ,Infectious Diseases ,chemistry ,Dolutegravir ,HIV-1 ,RNA, Viral ,Observational study ,business ,Heterocyclic Compounds, 3-Ring - Abstract
We aimed to investigate to what extent a first-line DTG-based ART regimen reduces HIV-RNA in semen compared to plasma.In this prospective, observational study, ART-naïve, HIV-infected males starting their first ART regimen with DTG plus TDF/FTC or ABC/3TC were enrolled. Paired blood (BP) and seminal plasma (SP) samples were collected at baseline (T0) and at week-2/4/12/24 after ART initiation. Sexually transmitted infections (STI) were ruled out before enrolment.Median baseline HIV-RNA levels were lower in SP compared to BP (657 versus 38.200 copies/ml, p 0.001), three subjects had undetectable semen HIV-RNA. After 12 weeks of treatment, HIV-RNA was below the quantification limit in both BP and SP of 11 pts (61.1%). Discordant results were obtained in 6 subjects (33.3%), showing quantifiable HIV-RNA in blood only (2 cases) and in semen only (4 cases). Finally, one subject had a positive HIV-RNA in SP/BP. At W24, only in 2/16 subjects (12.5%) HIV-RNA was detectable in semen, while in the others it was negative on SP/BP. No concurrent STI was found in subjects with detectable VL in semen.DTG demonstrated effectiveness in reducing VL with different kinetics in blood and semen, despite seminal viral suppression after 6 months of ART was not obtained in the totality of subjects.
- Published
- 2018
26. An intricate case of multidrug resistant Plasmodium falciparum isolate imported from Cambodia
- Author
-
Claudia Fabrizio, Laura Monno, Raffaele Dell’Acqua, Gioacchino Angarano, Annalisa Saracino, Francesco Castelli, Mariangela L’Episcopia, Francesco Di Gennaro, Sergio Lo Caputo, Michela Menegon, and Carlo Severini
- Subjects
Male ,Plasmodium vivax ,Case Report ,Drug resistance ,Vivax ,Lactones ,0302 clinical medicine ,MDR ,030212 general & internal medicine ,Artemisinin ,Malaria, Falciparum ,Antimalarials ,Cambodia ,Falciparum ,Genes ,Malaria ,Multiple ,Travel medicine ,Adult ,Artemisinins ,Atovaquone ,Coinfection ,Drug Combinations ,Humans ,Plasmodium falciparum ,Proguanil ,Quinine ,Treatment Outcome ,Drug Resistance, Multiple ,Travel ,Parasitology ,Infectious Diseases ,biology ,medicine.drug ,lcsh:Arctic medicine. Tropical medicine ,lcsh:RC955-962 ,030231 tropical medicine ,lcsh:Infectious and parasitic diseases ,03 medical and health sciences ,parasitic diseases ,medicine ,Malaria, Vivax ,lcsh:RC109-216 ,medicine.disease ,biology.organism_classification ,Virology ,Multiple drug resistance ,Genes, MDR - Abstract
Background Imported cases of multidrug resistant Plasmodium falciparum and treatment failure with artemisinin-based regimens, although rare, have been described also in Western countries and their management is often challenging. This is also due to an inadequate knowledge and implementation of health prevention measures. Case report A complex case of imported malaria caused by Plasmodium vivax/P. falciparum isolates in a patient who was not taking chemoprophylaxis while he was travelling in Cambodia is reported in this article. After failures of artemisinin-based and both oral and intravenous quinine-based regimens, a multidrug resistant P. falciparum was detected. The patient was successfully treated with atovaquone–proguanil. Conclusions This experience highlights the importance of a careful management that should be based not only on the most up-to-date guidelines, but also on the awareness of a rapidly evolving scenario.
- Published
- 2017
27. Dengue fever in travellers and risk of local spreading: case reports from Southern Italy and literature update
- Author
-
Claudia, Fabrizio, Luciana, Lepore, Maria, Chironna, Gioacchino, Angarano, and Annalisa, Saracino
- Subjects
Adult ,Dengue ,Male ,Travel ,Young Adult ,Italy ,Dominican Republic ,Humans ,Female ,Disease Notification ,Polynesia - Abstract
Dengue fever (DF), an arbovirosis caused by Dengue viruses (DV, serotypes 1-4), is responsible for an increasing number of travel-related acute febrile illnesses due to population growth, climate changes, spreading by viremic travellers, and improved laboratory diagnosis. The presence of efficient vectors (mosquito Aedes albopictus) has also been described in temperate regions including Italy which is considered the most heavily infected European country. Normally characterized by non-specific signs and symptoms, DF incidence is probably underestimated, especially in non-endemic countries, but the risk of severe forms is substantial. Between August and November 2013, five DF patients (4 males, age 23-38) were observed in the Infectious Disease Clinic (University of Bari, Southern Italy). All had just returned from DF endemic areas (2 French Polynesia, 3 Dominican Republic); 4/5 were hospitalized. Common clinical features included acute febrile syndrome, headache (2 with retro-orbital pain), rash (all patients), two with bleeding manifestations and one with gum bleeding. Laboratory tests demonstrated leukopenia (4 patients), elevated liver enzymes (3 patients), and thrombocytopenia (1 patient). Serum samples for DV antibodies and RNA detection were analyzed by the Regional Arbovirosis Reference Laboratory. Viral RNA was identified in 2/5 patients (DV-4) and seroconversion in the remaining cases. All patients made a complete recovery. Recent literature was reviewed, focusing on epidemiology and vector distribution (especially European and Italian territories), pathogenesis, clinical features, diagnosis, and treatment including vaccine strategies. The occurrence of 5 DF cases during the period of highest vector activity (June-November) in Italy emphasizes the risk of local outbreaks in temperate regions. This paper highlights the importance of clinical alert for dengue also in non-endemic countries.
- Published
- 2017
28. HCV clearance after direct-acting antivirals in patients with cirrhosis by stages of liver impairment: The ITAL-C network study
- Author
-
Nicola Napoli, Vincenzo Messina, Marianna Zappimbulso, Angelo Andriulli, Gianfranco Lauletta, Giuseppe Bruno, Teresa Santantonio, Raffaele Cozzolongo, Antonio Patrizio Termite, Salvatore Rizzo, C. Masetti, Antonina Smedile, Giuseppina Brancaccio, Antonio Massimo Ippolito, Pietro Gatti, Paolo Tundo, Fabio Conti, Claudia Fabrizio, Giovanni Battista Gaeta, Luca Fontanella, Michele Barone, Antonio Metrangolo, Giuseppe Cuccorese, Michele Milella, Ruggiero Francavilla, Filomena Morisco, Emanuela Ciracì, Vito Carretta, Maria Rosa Valvano, Pietro Andreone, Ippolito, Antonio Massimo, Milella, Michele, Messina, Vincenzo, Conti, Fabio, Cozzolongo, Raffaele, Morisco, Filomena, Brancaccio, Giuseppina, Barone, Michele, Santantonio, Teresa, Masetti, Chiara, Tundo, Paolo, Smedile, Antonina, Carretta, Vito, Gatti, Pietro, Termite, Antonio Patrizio, Valvano, Maria Rosa, Bruno, Giuseppe, Fabrizio, Claudia, Andreone, Pietro, Zappimbulso, Marianna, Gaeta, Giovanni Battista, Napoli, Nicola, Fontanella, Luca, Lauletta, Gianfranco, Cuccorese, Giuseppe, Metrangolo, Antonio, Francavilla, Ruggiero, Ciracì, Emanuela, Rizzo, Salvatore, and Andriulli, Angelo
- Subjects
Male ,Cirrhosis ,Databases, Factual ,Sustained Virologic Response ,Hepacivirus ,Antiviral therapy ,Direct-acting antivirals ,HCV ,Hepatitis C ,Liver cirrhosis ,Hepatology ,Gastroenterology ,Direct-acting antiviral ,Severity of Illness Index ,0302 clinical medicine ,Prospective Studies ,Stage (cooking) ,Prospective cohort study ,Multivariate Analysi ,biology ,Middle Aged ,Italy ,Liver ,030220 oncology & carcinogenesis ,Drug Therapy, Combination ,Female ,030211 gastroenterology & hepatology ,Human ,medicine.medical_specialty ,Logistic Model ,Liver Cirrhosi ,Antiviral Agents ,03 medical and health sciences ,Internal medicine ,Severity of illness ,medicine ,Humans ,Aged ,Antiviral Agent ,Hepaciviru ,business.industry ,medicine.disease ,biology.organism_classification ,Prospective Studie ,Logistic Models ,Multivariate Analysis ,Varices ,business - Abstract
Background Sustained virological response (SVR12) rates at 12 weeks after treatment for HCV-infected patients with decompensated cirrhosis are used when referring to those with moderate functional impairment, while few data are available for those with more severe impairment. The use of the cirrhosis staging system proposed by D’Amico might provide new insights on timing for antiviral therapy. Methods We investigated efficacy (SVR12), safety, and post-treatment variations in clinical and laboratory parameters in 2612 patients with advanced fibrosis (n = 575) or cirrhosis (n = 2037). Cirrhosis was in the compensated phase (without/with varices) or had previously been in the decompensated stage. Different direct-acting antiviral (DAA) regimens were administered in accordance with scientific guidelines. Results The SVR12 rate was 97.6% in patients with advanced fibrosis. For patients with cirrhosis, the rate was 96.5% in stage 1, 95.1% in stage 2, 100% in stage 3, 95.7% in stage 4, and 93.6% in stage 5. These rates were independent of gender, age, HCV genotype, and treatment schedule. Positive changes in biochemical parameters and CPT classes following therapy were evident in compensated and previously decompensated patients. Conclusion Our findings support the use of DAAs in patients with advanced cirrhosis (stages 3–5) who are at greatest risk and have the most to gain from therapy.
- Published
- 2017
29. Safety and effectiveness of a 12-week course of sofosbuvir and simeprevir ± ribavirin in HCV-infected patients with or without HIV infection: a multicentre observational study
- Author
-
Adele Giammario, Giuseppe Bruno, Raffaele Dell’Acqua, Alessandra Tartaglia, Giovanni Buccoliero, Luigia Scudeller, Salvatore Minniti, Gioacchino Angarano, Massimo Fasano, Eugenio Milano, Annalisa Saracino, Claudia Fabrizio, Nicoletta Ladisa, and Michele Milella
- Subjects
0301 basic medicine ,Microbiology (medical) ,Simeprevir ,Male ,medicine.medical_specialty ,Sofosbuvir ,Drug-Related Side Effects and Adverse Reactions ,Sustained Virologic Response ,Hepatitis C virus ,HIV Infections ,medicine.disease_cause ,Antiviral Agents ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Internal medicine ,Ribavirin ,medicine ,Humans ,Pharmacology (medical) ,Protease Inhibitors ,Adverse effect ,Aged ,Retrospective Studies ,Aged, 80 and over ,business.industry ,virus diseases ,Retrospective cohort study ,General Medicine ,Hepatitis C, Chronic ,Middle Aged ,digestive system diseases ,Regimen ,030104 developmental biology ,Infectious Diseases ,Treatment Outcome ,chemistry ,Italy ,Immunology ,Cohort ,030211 gastroenterology & hepatology ,Female ,business ,medicine.drug - Abstract
The combination of sofosbuvir and simeprevir ± ribavirin (SOF + SMV ± RBV) for hepatitis C virus (HCV) treatment has been associated with high rates of sustained virological response (SVR). Few data are available regarding this regimen in HIV/HCV co-infected patients. This study evaluated the effectiveness and safety of a 12-week course of SOF + SMV ± RBV in a cohort of HCV monoinfected and HIV/HCV co-infected individuals. HCV-infected patients, with or without HIV infection, receiving a 12-week course of SOF + SMV ± RBV in four Italian centres from February to October 2015, were included in this retrospective observational study. Clinical and biochemical data were retrieved for all patients. A total of 88 individuals were evaluated: 29 (33.0%) HIV/HCV co-infected and 59 (67.0%) monoinfected. Most patients were males with HCV genotype 1b (62.5%) and 1a (25%) infection. RBV was used in 41 HCV monoinfected and 6 HIV/HCV co-infected patients. Cirrhosis was found in 67 patients (76.1%). The most common adverse events (AEs) were rash and/or pruritus (23.9%), fatigue (13.6%) and anaemia (9.1%). Serious AEs occurred in three patients (3.4%). No treatment discontinuations were observed. RBV use was associated with multiple AEs (P = 0.02). An overall SVR12 of 93.2% was achieved; 96.6% in HCV monoinfected and 86.2% in HIV/HCV co-infected individuals, without significance both in univariate (P = 0.09) and multivariate analyses (P = 0.12). A baseline platelet count ≥90 000/mm3 was associated with higher rates of SVR (P = 0.005). A 12-week course of SOF + SMV ± RBV was associated with good safety and high SVR12 rate both in HCV monoinfected and HIV-HCV co-infected individuals.
- Published
- 2016
30. Comment on: Integrase strand-transfer inhibitor polymorphic and accessory resistance substitutions in patients with acute/recent HIV infection
- Author
-
Claudia Fabrizio, Antonella Lagioia, Grazia Punzi, Luciana Lepore, Gioacchino Angarano, Annalisa Saracino, and Laura Monno
- Subjects
0301 basic medicine ,Pharmacology ,Microbiology (medical) ,Genetics ,030106 microbiology ,Human immunodeficiency virus (HIV) ,Biology ,medicine.disease_cause ,Virology ,03 medical and health sciences ,Integrase strand transfer inhibitor ,0302 clinical medicine ,Infectious Diseases ,medicine ,Pharmacology (medical) ,In patient ,030212 general & internal medicine - Published
- 2017
31. Hepatic encephalopathy in the course of anti-HCV therapy with paritaprevir/ritonavir, ombitasvir, dasabuvir and ribavirin
- Author
-
Francesco Resta, Claudia Fabrizio, Annalisa Saracino, Gioacchino Angarano, and Michele Milella
- Subjects
Microbiology (medical) ,Dasabuvir ,business.industry ,Anti hiv ,Ribavirin ,General Medicine ,medicine.disease ,Virology ,Ombitasvir ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Infectious Diseases ,chemistry ,Paritaprevir ,medicine ,Pharmacology (medical) ,Ritonavir ,030212 general & internal medicine ,business ,Hepatic encephalopathy ,030217 neurology & neurosurgery ,medicine.drug - Published
- 2016
32. Prevalence of diabetes mellitus in newly diagnosed pulmonary tuberculosis in Beira, Mozambique
- Author
-
Damiano Pizzol, Laura Monno, Giovanni Putoto, Claudia Fabrizio, Kajal D. Chhaganlal, Annalisa Saracino, and Francesco Di Gennaro
- Subjects
Adult ,Male ,Pediatrics ,medicine.medical_specialty ,Tuberculosis ,Urban Population ,Diabetes mellitus, pulmonary tuberculosis, Beira, Mozambique ,030231 tropical medicine ,Newly diagnosed ,Overweight ,Impaired glucose tolerance ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,Pulmonary tuberculosis ,Diabetes mellitus ,Diabetes Mellitus ,Prevalence ,Urban Health Services ,medicine ,Humans ,030212 general & internal medicine ,Tuberculosis, Pulmonary ,Mozambique ,Aged ,business.industry ,Mean age ,Articles ,General Medicine ,Middle Aged ,medicine.disease ,Female ,medicine.symptom ,Pulmonary tb ,business - Abstract
Introduction: Data regarding the association between diabetes mellitus (DM) and tuberculosis (TB) in Africa are scarce. DM screening among TB patients in Mozambique was carried out. Methods: The study was implemented from January to August 2016 in three Urban Health Centers in Beira, Mozambique and recruited adult (>18 years) patients newly diagnosed with pulmonary TB. Results: Three hundred and one patients were enrolled (67.4%, males mean age 31.7(SD 11 years). Diabetes was diagnosed in only 3 patients (1%) and impaired glucose tolerance (IGT) in an additional 6 subjects (2%). Conclusion: A lower than expected prevalence of DM was observed, which could be explained by the lack of traditional risk factors for DM (overweight, age over 45 years, hypertension and smoking) in Mozambique. Keywords: Diabetes mellitus, pulmonary tuberculosis, Beira, Mozambique
- Published
- 2017
33. DAA-based treatment in HCV and HIV/HCV co-infected patients in real world: data from a large single-centre experience
- Author
-
G. Angarano, Nicoletta Ladisa, Giuseppe Bruno, Laura Monno, Claudia Fabrizio, Michele Milella, Raffaele Dell’Acqua, Eugenio Milano, and Annalisa Saracino
- Subjects
Single centre ,Hepatology ,business.industry ,Medicine ,business ,Virology ,Real world data - Published
- 2017
34. Hepatitis C virus clearance after direct-acting antivirals in cirrhotic patients by stages of liver impairment: the ITAL-C network study
- Author
-
Antonio Metrangolo, Giuseppe Bruno, Pietro Gatti, Salvatore Rizzo, Antonio Massimo Ippolito, Michele Milella, Emanuela Ciracì, Gianfranco Lauletta, Piera Tundo, Luca Fontanella, Teresa Santantonio, C. Masetti, Claudia Fabrizio, Michele Barone, Fabio Conti, P. Andreone, Vincenzo Messina, Angelo Andriulli, M. Zappimbulso, Massimo Fasano, G.B. Gaeta, Giuseppe Cuccorese, Antonio Patrizio Termite, Nicola Napoli, Gianluca Brancaccio, A. Smedile, Raffaele Cozzolongo, Francesco Morisco, Vito Carretta, Maria Rosa Valvano, and Ruggiero Francavilla
- Subjects
03 medical and health sciences ,0302 clinical medicine ,Hepatology ,business.industry ,030220 oncology & carcinogenesis ,Hepatitis C virus ,Medicine ,030211 gastroenterology & hepatology ,business ,DIRECT ACTING ANTIVIRALS ,medicine.disease_cause ,Virology - Published
- 2017
35. International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK
- Author
-
Luciana Teofili, Pascal Bessong, Christine Sekaggya-Wiltshire, Evangelia Georgia Kostaki, André Silva Marques Pinto, Elena Ricci, Rachel Cassidy, Andrew Ustianowski, Sara Croxford, Gloria Samperiz, Brenda Crabtree-Ramírez, Enrique Bernal Morell, Magnus Gisslen, PIERANGELO CHINELLO, LUZ MARTÍN CARBONERO, Ignacio Pérez Valero, Jonathan Mok, Charalampos Moschopoulos, António Guerra Maio, Niklaus Daniel Labhardt, Thomas Lengauer, Anna Bonjoch, Clifford Leen, Cheryl Johnson, Caterina Uberti-Foppa, CARLO FEDERICO PERNO, Tomasz Mikuła, Susanne Dam Nielsen, Roberta Gagliardini, Miguel Garcia Deltoro, Borja Mora Peris, Pierluca Piselli, Santiago Roura, Verena Keitel, Eirini Christaki, Jose Molto, ÁNGELA GUTIÉRREZ LIARTE, Nezam Afdhal, Samira Fafi-Kremer, Sofia Jordão, Giuseppe Corano Scheri, Sofia De Azeredo Pereira, CARMEN MARIA GONZALEZ DOMENECH, ALLAN BUZIBYE, Paula Meireles, Thumbi Ndung'u, Valerie Delpech, David Nicolás, Jeffrey V. Lazarus, Matti Ristola, Rosário Serrão, Gordana Avramovic, Christoph Spinner, John Lambert, Jane Anderson, Helena Cortes Martins, Kamilla Grønborg Laut, Hasina Samji, Juan Pasquau, Tomasz Smiatacz, Rosa De Miguel Buckley, Stephanie Raymond, GIOVANNI FRANCESCO PELLICANO', Claudia Fabrizio, Alfredo Minguela, Dan Otelea, Sebastian Noe, Annalisa Saracino, Marco Iannetta, Ashutosh Tamhane, Samantha Elizabeth De Jesus, António Sarmento, Emma Thomson, Bart Rijnders, Agnes LIBOIS, Elisa De Lazzari, Alessandra D'Abramo, Andrei Vata, Hans Jakob Hartling, Henrik Ullum, Roman Pfeifer, Alice Trentalange, Stefano Malinverni, Gianmaria Baldin, and Mark Bower
- Subjects
0301 basic medicine ,medicine.medical_specialty ,business.industry ,030106 microbiology ,Public Health, Environmental and Occupational Health ,Human immunodeficiency virus (HIV) ,medicine.disease_cause ,03 medical and health sciences ,0302 clinical medicine ,Infectious Diseases ,Pharmacotherapy ,Family medicine ,International congress ,medicine ,030212 general & internal medicine ,business - Published
- 2016
36. Diachrony and morphological equilibrium. The case of the southern New Indo-Aryan verb
- Author
-
Milizia, Paolo, Paolo Milizia, Michela Cennamo, Claudia Fabrizio, and Milizia, Paolo
- Subjects
Indo-Aryan Languages ,Morphology ,Indo-Aryan Languages, Morphology ,Marathi, Konkani, Verb, Paradigm, Syncretism, Inflectional homonymy, Historical linguistics, Exponence - Abstract
Marathi-Konkani varieties exhibit a series of verbal formations that derive from the univerbation of a participle plus a form of ‘be’. In the creation of these new, resynthesised, sections of the verbal paradigm, several instances of systematic homonymies arose, which recurrently involve the cells of the first and second person plural and affect several dimensions of the paradigm (aspect syncretism, mood syncretism and gender-agreement syncretism are all observed). At the same time, in inherited synthetic verb forms, the first and second person plural cells show neutralisation of inflection-class distinctions. According to the analysis proposed here, these homonymies can be exhaustively explained neither in terms of phonological development, nor with reference to the characteristics of morphosyntactic properties, but are at least in part due to a general tendency to “morphological equilibrium” that disfavours non-syncretic cumulative exponents uniquely associated with critically rare paradigm-cells.
- Published
- 2019
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.